Welcome to our dedicated page for Medicure news (Ticker: MCUJF), a resource for investors and traders seeking the latest updates and insights on Medicure stock.
Medicure (MCUJF) delivers innovative therapeutic solutions through pharmaceutical development and direct-to-consumer pharmacy services. This page provides authorized updates on the company's clinical advancements, regulatory milestones, and strategic business decisions.
Access real-time press releases covering earnings reports, drug development progress (including MC-1 clinical trials), and operational expansions like the Gateway Medical Pharmacy acquisition. Investors will find essential updates on Marley Drug's nationwide distribution network and regulatory designations such as Orphan Drug statuses.
Our curated news feed serves as a comprehensive resource for tracking Medicure's dual focus on cardiovascular treatments and neurometabolic disorder solutions. Stay informed about product commercialization efforts, intellectual property developments, and compliance achievements that shape the company's market position.
Bookmark this page for verified updates on Medicure's pharmaceutical innovations and pharmacy service enhancements. Check regularly for new developments in therapeutic research and healthcare distribution strategies.
Medicure Inc. (TSXV:MPH)(OTC PINK:MCUJF) reported financial results for Q2 2024. Total net revenue decreased to $5.2 million from $6.0 million in Q2 2023. AGGRASTAT sales declined to $1.8 million from $2.6 million. Marley Drug business revenue remained stable at $2.7 million. ZYPITAMAG sales increased slightly to $1.4 million from $1.3 million. The company reported a net loss of $1.2 million ($0.12 per share) compared to a net income of $253,000 ($0.03 per share) in Q2 2023. Adjusted EBITDA was negative $514,000, down from $948,000. Cash and cash equivalents stood at $5.9 million as of June 30, 2024.
Medicure, a pharmaceutical company, announced an asset purchase agreement with CanAm Bioresearch to acquire patents and intellectual property related to new chemical entities for therapeutic use. Medicure will pay CanAm $100,000 upfront and up to $1.25 million in milestone payments, plus 10% of net proceeds from asset-related transactions, capped at $20 million. The deal includes the option for CanAm to repurchase the assets if Medicure fails to file an IND application within seven years. The agreement remains subject to regulatory approvals and customary closing conditions.
Medicure (TSXV:MPH) (OTC PINK:MCUJF) reported financial results for Q1 2024, ending March 31, 2024. The company recorded net revenue of $5.7 million, a slight increase from $5.6 million in Q1 2023. AGGRASTAT revenue fell to $2.3 million from $2.7 million, while Marley Drug revenue rose to $2.7 million from $2.3 million. Adjusted EBITDA decreased to $359,000 from $916,000, and net income dropped to $51,000 from $290,000. The decrease was attributed to higher expenses and lower AGGRASTAT sales. The company had $6.1 million in unrestricted cash as of March 31, 2024.
Additionally, all six nominees, including new director Kimberly Kramchynsky, were elected at the annual general meeting. The company will host a conference call on May 29, 2024, to discuss the results.
FAQ
What is the current stock price of Medicure (MCUJF)?
What is the market cap of Medicure (MCUJF)?
